



## Minutes of the GM Formulary Subgroup meeting

**Date:** 5th February 2015, 12-2pm

**Venue:** Pharmacy seminar room, University Hospital of South Manchester, Southmoor Road, Wythenshawe

**In attendance:** Charlotte Skitterall, Helen Burgess, Jimmy Cheung, Leigh Lord, Monica Mason, Liz Bailey, Connie Chen, Claire Vaughan, Dev Devapriya, Peter Howarth, Ann Harrison, Sarah Jacobs

**Apologies:** Aidín Cooke, Lorraine Booth

**Declarations of interest:** HB – declared an interest in item 5a following attendance at a Duoresp advisory board meeting. AH – confirmed a change in employer.

**Item 3 – Previous minutes and actions** - The minutes from the Dec meeting were agreed as accurate, there was no meeting held in January.

**Action:** Send the word version to GMMMG, thereafter add to website

### Item 4 a- Update from OAB meeting on 7th January

CS updated the FSG on this meeting, in which a draft pathway was developed. SJ had sent out notes of the meeting and this draft pathway to the attendees and comments were requested. CV was communicating with the urology pharmacist at Salford also. In addition to drug choice there was discussion around the development of diaries to aid modification of lifestyle factors prior to treatment. Nicola Bennet has agreed to gather further information on the local services available, and CS will communicate further with the group to seek further comments.

The FSG agreed that the revised version of chapter 7 should be sent to GMMMG in Feb and any changes resulting from the pathway development would be incorporated into the pathway at a later date.

**Action:** CS, CV and SJ to communicate further with the OAB pathway group to bring a draft pathway for approval back to the March FSG

CS to remind NB regarding gathering information on local services available.

### Item 4 b - Request from GSK to use the formulary in recorded web meetings – reply from GMMMG

The FSG received feedback from GMMMG regarding production of a recorded web meeting to promote the formulary across GM. GMMMG are keen for a generic version of this idea to be facilitated via the ABPI and for FSG to take this forward. The FSG discussed this further but would prefer that this material be produced by the NHS and may be suitable for funding from NHS innovations. The FSG thought that it would be more useful if all GM subgroups were asked to participate in the production of this material.

**Action:** Communicate suggestions from FSG to GMMMG

### Item 4 c – Statin information within chapter 2 in relation to the updated NICE CG181

The group discussed amendments to the statin content of the formulary in light of NICE CG181. It was suggested that simvastatin be removed from the first choice section and that pravastatin 10mg be removed from the alternatives section, with a note that pravastatin should be reserved for those unsuitable for either atorvastatin or simvastatin. The FSG asked for some prescribing data relating to pravastatin to be circulated.

**Action:** Circulate pravastatin prescribing data to the FSG by email following the meeting.

Amend chapter 2 as suggested by the FSG

#### **Item 4 d – Vacant position – vice-chair of FSG**

The FSG voted in Helen Burgess as the vice-chair of the FSG.

**Action:** Communicate position to GMMMG

#### **Item 4 e – New FSG member**

Jonathon Peacock who will be taking up the position of deputy chief pharmacist at WWL will join the FSG in March

**Action:** Send Dol and papers to JP

#### **Item 5– New product applications**

**Duoresp Spiromax®** – The group assessed this agent for inclusion within the formulary as per the formulary inclusion criteria. As it has demonstrated bioequivalence to Symbicort in adults (EMA) and is less costly than Symbicort the FSG have recommended it for use as an option in chapter 3.2 (combination LABA/ICS inhalers). It will not replace Symbicort within the formulary due to a lack of the lower strength preparation.

**Action:** Submit FSG recommendation to GMMMG for ratification, thereafter update chapter 3 of website

**Tapentadol MR** - The group assessed this agent for inclusion within the formulary as per the formulary inclusion criteria. The group noted the NTS recommendation and agreed that this agent would not meet the criteria for inclusion within the formulary as it should be restricted for those patients with severe chronic pain. The FSG assessed the agent for addition to the Grey List and agreed that tapentadol should be added to the Grey List “for restricted use in the treatment of severe chronic pain which can be adequately managed only with opioid analgesics.” The interface subgroup will be asked to assess the agent for the RAG list

**Action:** Submit FSG recommendation to GMMMG for ratification, thereafter update the grey list. Submit agent to the IPS for RAG assessment.

#### **Item 6-formulary amendments**

The FSG reviewed MHRA drug safety alerts, NICE guidance and NTS recommendations from January 2015 and agreed to amend the formulary as appropriate. This included the addition of a black triangle to sodium valproate, warnings of exfoliative dermatitis with ustekinumab and hypogammaglobulinaemia and bronchiectasis with mycophenolate mofetil included in chp 13.5.3. There were no published recommendations to consider from NTS however at the request of NTS ondansetron melts for Meniere’s Disease were removed from the formulary due to this being an unlicensed use with a lack of evidence.

The group noted an application for Ultrabase to the formulary and information regarding the “Eczema Expert trial”, both of which will be included within the chapter 13 review.

**Action:** Submit FSG recommendation to GMMMG for ratification

#### **Item 7- Review of formulary chapters:**

**Chapter 7 review** – The group concluded the review of chapter 7 and asked that it be submitted to GMMMG for approval

**Action:** Submit to GMMMG for approval, thereafter this chapter will be formatted and will replace the current version of chapter 7 on the website

**Chapter 10 review** - The group concluded the review of chapter 10 and asked that it be submitted to GMMMG for approval

**Action:** Submit to GMMMG for approval, thereafter this chapter will be formatted and will replace the current version of chapter 10 on the website

#### **Item 8- DNP and Grey List**

##### **a) Assessment of DNP and Grey list content with regards paediatrics**

Following request from GMMMG regarding the applicability of the DNP and Grey list in paediatric patients, the FSG assessed these lists for appropriateness of content in relation to paediatrics, and agreed that the content was appropriate to both adults and children. The FSG agreed that the message on the website be amended to state that these agents were not suitable for prescribing in adults and children.

The FSG were made aware of some further possible additions to the lists which will be agreed at the March FSG meeting

**Action:** Submit to GMMMG for ratification thereafter amend website .Bring necessary information to the March FSG meeting.

**Item 9 –** Feedback from GMMMG: There was no GMMMG meeting in January

**AOB:** Nothing to discuss

**AOB -** The FSG suggested changes to the way NICE TAs are listed within the formulary and the appropriate referencing of NICE CGs but will consider this further at the March meeting

Date of next meeting: Thursday 5th March 2015, 12-2pm  
Sale Suite  
Trafford CCG,  
1st Floor, Crossgate House, Cross Street, Sale, M33 7FT